← Back to headlines
MAIA Biotechnology seeks $33M capital raise for Phase 3 anticancer therapy trial
MAIA Biotechnology announced its expectation to raise $33 million in capital. The funding is intended to finance the Phase 3 clinical trial of its anticancer therapy.
8 Apr, 13:13 — 8 Apr, 13:13
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Customs Intercepts P156.4 Million in Smuggled Cigarettes at Davao Port
just now
Bureau of Customs Shreds P266 Million in Smuggled Cigarettes in Zamboanga City
just now
Subic Bay Tourism Firm Flags Security Breach Involving Convicted American
just now